Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 70, Issue 2, Pages 380-383Publisher
B M J PUBLISHING GROUP
DOI: 10.1136/ard.2010.137281
Keywords
-
Categories
Ask authors/readers for more resources
Background Anti-beta(2)-glycoprotein-I (anti-beta(2)GPI) were demonstrated to be pathogenic in the antiphospholipid syndrome (APS). However, they can be detected in patients with no features of APS, especially those affected by systemic autoimmune diseases (SAD), and so in healthy children. It has been suggested that anti-beta(2)GPI against domain 1 (D1) associate with thrombosis, while those recognising domain 4/5 (D4/5) are present in non-thrombotic conditions. Objective To evaluate the fine specificity of anti-beta(2)GPI in adults and infants. Methods Three groups were examined-group A: 57 1-year-old healthy children born to mothers with SAD; group B: 33 children with atopic dermatitis; group C: 64 patients with APS. Subjects were selected based on positive anti-beta(2)GPI IgG results. Serum samples were tested for anti-beta(2)GPI IgG D1 and D4/5 using research ELISAs containing recombinant beta(2)GPI domain antigens. Results Children (A and B) displayed preferential IgG reactivity for D4/5, whereas patients with APS were mainly positive for D1. No thrombotic events were recorded in groups A and B. Conclusions The specificity for D4/5 suggests that anti-beta(2)GPI IgG production in children born to mothers with SAD is a process neither linked to systemic autoimmunity nor related to the maternal autoantibody status. This unusual fine specificity might, at least partially, account for the 'innocent' profile of such antibodies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available